DibbsBarker is pleased to announce that Lis Boyce, Partner, has been elected to the firm’s Board.
Lis is a Partner in the firm’s Commercial Services Group and leads the firm’s Corporate Governance team in the Sydney office. Lis is also the leader of the the firm’s National Medical & Pharmaceutical Industry Group.
Lis has practised almost exclusively in the area of commercial law for 25 years. Since joining the firm in 1989, she has assisted clients with matters relating to corporate governance, complex contracts, franchising, mergers and acquisitions, and ASX listing. Lis has been a partner at the firm for 15 years.
With specialist expertise in corporate governance, Lis frequently publishes articles on topics such as continuous disclosure and directors’ duties. She has also previously published articles on the James Hardie, Centro and Fortescue cases.
Lis frequently presents on corporate governance topics, including participating in Australian Institute of Company Directors Briefings on the ‘Two Strikes Rule’ and more recently on the topic of ‘Board Evaluation’. Lis also led the firm’s collaboration with the UTS Centre for Corporate Governance several years ago, where the firm sponsored research in the changing roles and responsibilities of company directors.
Given Lis’ broad range of corporate experience in advising clients on their structure, governance, operations and strategy, she is well placed to assist her own firm.
Lis is the Chairman of the NSW Committee of AusMedtech, a division of AusBiotech dedicated to the advancement of the Australian medical technology industry. She is also a member of the Australian Institute of Company Directors, the Commercial Law Association and the Financial Services Institute of Australasia.
For a brief profile on Lis Boyce, please click here
. For any further information, please contact: